European Heart Journal

Journal

Publication Venue For

  • Lung function impairment and risk of incident heart failure: the NHLBI Pooled Cohorts Study.  43:2196-2208. 2022
  • Alirocumab after acute coronary syndrome in patients with a history of heart failure.  43:1554-1565. 2022
  • PDAY risk score predicts cardiovascular events in young adults: the CARDIA study. 2022
  • Effects of dapagliflozin on mortality in patients with chronic kidney disease: A pre-specified analysis from the DAPA-CKD randomized controlled trial.  42:1216-1227. 2021
  • Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering:ODYSSEY OUTCOMES trial.  41:4245-4255. 2020
  • Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: Prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial.  41:4114-4123. 2020
  • Salt and cardiovascular disease: Insufficient evidence to recommend low sodium intake.  41:3363-3373. 2020
  • Hypertensive coronary microvascular dysfunction: A subclinical marker of end organ damage and heart failure.  41:2366-2375. 2020
  • Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: An ODYSSEY OUTCOMES trial analysis.  41:2248-2258. 2020
  • Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: A propensity-matched analysis of Medicare claims data.  40:3046-3054. 2019
  • Effects of alirocumab on types of myocardial infarction: Insights from the ODYSSEY OUTCOMES trial.  40:2801-2809. 2019
  • Cardiovascular outcome trials in patients with chronic kidney disease: Challenges associated with selection of patients and endpoints.  40:880-886. 2019
  • Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification.  40:441-451. 2019
  • Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study.  39:3641-3653. 2018
  • Take a blood pressure pill or benefit from renal denervation?.  39:3010-3012. 2018
  • Final Farewell to Alberto Zanchetti MD..  39:2616-2617. 2018
  • The circadian clock in cardiovascular regulation and disease: Lessons from the Nobel Prize in Physiology or Medicine 2017.  39:2326-2329. 2018
  • Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials.  39:1687-1697. 2018
  • International recommendations for electrocardiographic interpretation in athletes.  39:1466-1480. 2018
  • Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction.  39:840-849. 2018
  • The technical report on sodiumintake and cardiovascular disease in low- and middleincome countries by the joint working group of theWorld Heart Federation, the European Society of Hypertension and the European Public Health Association.  38:712-719. 2017
  • Comparative efficacy of coronary artery bypass surgery vs. percutaneous coronary intervention in patients with diabetes andmultivessel coronary artery disease with or without chronic kidney disease.  37:3440-3447. 2016
  • Valvular heart disease in older adults: Seeking an ounce of prevention.  37:3523-3524. 2016
  • Cardiac structure and function and leisure-time physical activity in the elderly: The Atherosclerosis Risk in Communities Study.  37:2544-2551. 2016
  • CardioPulse. The SPRINT trial results.  37:924-927. 2016
  • The SPRINT trial results.  37:925-927. 2016
  • Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction.  37:466-472. 2016
  • Mechanical Dyssynchrony: A Risk Factor but not a Target.  37:60-62. 2016
  • Alcohol consumption and risk of heart failure: The Atherosclerosis Risk in Communities Study.  36:939-945. 2015
  • Function over form? Assessing the left atrium in heart failure.  36:711-714. 2015
  • Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension.  36:623-631. 2015
  • Predictors of blood pressure response in the SYMPLICITY HTN-3 trial.  36:219-227. 2015
  • Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction.  35:3442-3451. 2014
  • Heart failure with preserved ejection fraction: A forest of a variety of trees.  35:3410-3412. 2014
  • A rare coronary anomaly: Origin of the right coronary artery from the left ventricular outflow tract.  35:2811. 2014
  • Combined intracardiac and epicardial device closure of a large left ventricular pseudoaneurysm.  35:2031. 2014
  • Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48.  35:1457-1465. 2014
  • Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction.  35:42-47. 2014
  • Prevention of liver cancer cachexia-induced cardiac wasting and heart failure.  35:932-941. 2014
  • Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: Findings from post hoc propensity-matched analysis of the AFFIRM trial.  34:1489-1497. 2013
  • Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency.  34:676-683. 2013
  • Phenotypic and pathophysiological heterogeneity in heart failure with preserved ejection fraction..  33:1716-1717. 2012
  • Physiological concentration of glutamine increases exogenous fatty acid utilization in the ex vivo working heart: role of the hexosamine biosynthetic pathway.  32:1003-1003. 2011
  • Relationship between improvement in left ventricular dyssynchrony and contractile function and clinical outcome with cardiac resynchronization therapy: The MADIT-CRT trial.  32:1720-1729. 2011
  • Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction.  32:1227-1234. 2011
  • Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: Potential mechanistic insights from epidemiological data.  32:712-720. 2011
  • Boomerang-shaped heart in isolated dextroversion.  32:247. 2011
  • A history of atrial fibrillation and outcomes in chronic advanced systolic heart failure: A propensity-matched study.  30:2029-2037. 2009
  • Fish consumption, marine omega-3 fatty acids, and incidence of heart failure: A population-based prospective study of middle-aged and elderly men.  30:1495-1500. 2009
  • Dipyridamole promotes ischemia-induced angiogenesis and tissue blood flow in critical limb ischemia througha PKA dependent nitric oxide pathway.  29:241-241. 2008
  • A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure.  28:1334-1343. 2007
  • Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients.  28:1440-1447. 2007
  • Digoxin and reduction in mortality in systolic and diastolic heart failure at low serum digoxin concentrations [5].  27:1630. 2006
  • Heart failure, chronic diuretic use, and increase in mortality and hospitalization: An observational study using propensity score methods.  27:1431-1439. 2006
  • Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: Results from the NIH-NHLBI-sponsored Women's Ischaemia Syndrome Evaluation (WISE) study.  27:1408-1415. 2006
  • Digoxin and reduction in mortality and hospitalization in heart failure: A comprehensive post hoc analysis of the DIG trial.  27:178-186. 2006
  • Hormone treatment - Misconceptions and agreements [4] (multiple letters).  23:89-91. 2002
  • Hormone treatment--misconceptions and agreements..  23:89-91. 2002
  • Intravenous NPA for the treatment of infarcting myocardium early: InTIME-II, a double-blind comparison on of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction.  21:2005-2013. 2000
  • Simultaneous imaging of transmembrane potential and intracellular calcium in myocyte cultures.  21:549-549. 2000
  • Abciximab therapy in percutaneous intervention: economic issues in the United States..  19 Suppl D:D52-D58. 1998
  • Increased platelet activation and fibrinogen in Asian Indians. Potential implications for coronary risk.  19:720-726. 1998
  • Single right coronary artery assessed by contrast angiography and transoesophageal echocardiography.  16:1739-1741. 1995
  • International Standard Serial Number (issn)

  • 0195-668X
  • Electronic International Standard Serial Number (eissn)

  • 1522-9645